382 The synthetic long peptide cancer vaccine UV1 in combination with ipilimumab induces a CD4+ Th1 anti-hTERT immune response and an inflammatory tumor microenvironment in patients with melanoma

• Sara Mangsbo,
• Eivind Hovig,
• Nadia Mensali,
• Espen Ellingsen,
• Iliana Kerzeli,
• Irantzu Anzar,
• Trevor Clancy,
• Steinar Aamdal,
• Elin Aamdal,
• Tormod Guren,
• Else-Marit Inderberg-Suso,
• Gustav Gaudernack

Affiliations

Sara Mangsbo

Uppsala University, Uppsala, Sweden

Eivind Hovig

2Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Part of Oslo University Hospital, Oslo, Norway

Nadia Mensali

Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway

Espen Ellingsen

1Ultimovacs ASA, Oslo, Norway

Iliana Kerzeli

2Uppsala University, Uppsala, Sweden

Irantzu Anzar

3NEC Oncoimmunity, Oslo, Norway

Trevor Clancy

3NEC Oncoimmunity, Oslo, Norway

Steinar Aamdal

1Ultimovacs ASA, Oslo, Norway

Elin Aamdal

4Oslo University Hospital, Oslo, Norway

Tormod Guren

4Oslo University Hospital, Oslo, Norway

Else-Marit Inderberg-Suso

4Oslo University Hospital, Oslo, Norway

Gustav Gaudernack

1Ultimovacs ASA, Oslo, Norway